Navío S, Allona A, Serrano A, Vallejo J, del Hoyo J, Rivas J A, Escudero A
Servicio de Urología, Hospital Ramón y Cajal.
Actas Urol Esp. 1993 Jan;17(1):62-7.
The study includes 138 patients with erectile dysfunction, all of them previously treated with intracavernous injections. Following study and classification of the type of impotence, they were all included in one of the four following groups. The drugs used were, in group I (73 patients) Prostaglandins E1, in group II (37 patients) Papaverine, in group III (6 patients) a combination of Papaverine and Phentolamine and in group IV (22 patients) a combination of Papaverine and Prostaglandins E1. We found a good treatment response in 59.3% cases (60.3% in group I, 51.3% in group II, 66.7% in group III, and 69% in group IV). We outline the better results obtained in group IV, as well as the reduced number of complications in our series.
该研究纳入了138例勃起功能障碍患者,他们之前均接受过海绵体内注射治疗。在对阳痿类型进行研究和分类后,他们全部被纳入以下四组之一。所使用的药物为,第一组(73例患者)使用前列腺素E1,第二组(37例患者)使用罂粟碱,第三组(6例患者)使用罂粟碱和酚妥拉明的组合,第四组(22例患者)使用罂粟碱和前列腺素E1的组合。我们发现59.3%的病例治疗反应良好(第一组为60.3%,第二组为51.3%,第三组为66.7%,第四组为69%)。我们概述了第四组取得的更好结果以及我们系列中并发症数量的减少情况。